Sign inCreate account

Report workspace tools

NCT04589845ACTIVE_NOT_RECRUITINGanonymous

Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Phase II Platform Trial

Sponsor

Source record

Hoffmann-La Roche

Phase

Source record

Phase II

Modality

AI-normalized

small molecule

Target

AI-normalized

Solid Tumors with specific oncogenic genomic alterations or TMB-high

Indication / condition

AI-normalized

Solid Tumors

Intervention

Source record

Entrectinib, Entrectinib, Alectinib, Atezolizumab, Ipatasertib, Trastuzumab emtansine, Inavolisib, Belvarafenib, Pralsetinib, Divarasib, Camonsertib

Source & freshness

Source record

NCT ID

NCT04589845

Original source

ClinicalTrials.gov

Source last updated

May 08, 2026

Ingested at

Jun 05, 2026

Internal sync

Jun 05, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT04589845

Title

Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Phase II Platform Trial

Sponsor

Hoffmann-La Roche

Status

ACTIVE_NOT_RECRUITING

Phase

Phase II

Condition raw

Solid Tumors

Condition normalized

Solid Tumors

Modality raw

small molecule

Modality normalized

small molecule

Target raw

Entrectinib, Entrectinib, Alectinib, Atezolizumab, Ipatasertib, Trastuzumab emtansine, Inavolisib, Belvarafenib, Pralsetinib, Divarasib, Camonsertib

Target normalized

Solid Tumors with specific oncogenic genomic alterations or TMB-high

Interventions

Entrectinib, Entrectinib, Alectinib, Atezolizumab, Ipatasertib, Trastuzumab emtansine, Inavolisib, Belvarafenib, Pralsetinib, Divarasib, Camonsertib

Public preview

Source record

The TAPISTRY study, sponsored by Hoffmann-La Roche, is a global, multicenter, open-label trial evaluating the safety and efficacy of targeted therapies and immunotherapies in patients with unresectable, locally advanced, or metastatic solid tumors. The trial aims to personalize treatment based on genomic profiling, potentially enhancing therapeutic outcomes.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Phase II Platform Trial

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT04589845

Status

ACTIVE_NOT_RECRUITING

Phase

Phase II

Sponsor

Hoffmann-La Roche

Executive brief

Investment-Ready Snapshot

The TAPISTRY study, sponsored by Hoffmann-La Roche, is a global, multicenter, open-label trial evaluating the safety and efficacy of targeted therapies and immunotherapies in patients with unresectable, locally advanced, or metastatic solid tumors. The trial aims to personalize treatment based on genomic profiling, potentially enhancing therapeutic outcomes.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedMay 08, 2026
Internal syncJun 05, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT04589845

Indication

Solid Tumors

Modality

small molecule

Target

Solid Tumors with specific oncogenic genomic alterations or TMB-high

Intervention

Entrectinib, Entrectinib, Alectinib, Atezolizumab, Ipatasertib, Trastuzumab emtansine, Inavolisib, Belvarafenib, Pralsetinib, Divarasib, Camonsertib

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.